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Presynaptic Inhibition of Norepinephrine 
Release From Sympathetic Nerve 
Endings by Endogenous Adenosine
G erard A. Rongen, Jacques W.M. Lenders, Jorgo Lambrou, Jacques J. Willemsen,
H erm an Van Belle, Theo Thien7 Paul Smits
Abstract A TP is coreleased with norepinephrine from 
sympathetic nerve endings and subsequently broken down to 
adenosine. In animal preparations, adenosine can inhibit n o r­
epinephrine release by stimulation of presynaptic receptors. 
We tested this feedback mechanism in humans by using a 
specific nucleoside transport inhibitor (draflazine) as a p h ar­
macological tool to  allow accumulation of endogenous adeno­
sine in the synaptic cleft. In a dose-finding study on draflazine 
infusions into the brachial artery ( n = 10 ), we identified an 
optimal dose of 250 ng/min per deciliter of forearm tissue that 
induced considerable local nucleoside transport inhibition (ap ­
proximately 40%) without systemic effects. In the main study, 
we investigated the effects of this draflazine dose on sympa- 
thetic-mediated norepinephrine spillover during lower body
negative pressure ( - 2 5  mm Hg) by use of the [3H]norepineph- 
rine isotope dilution technique (n= 25). Lower body negative 
pressure induced a significant increase in total body norepineph­
rine spillover, forearm norepinephrine appearance rate, forearm 
vascular resistance, and heart rate. During draflazine infusion into 
the brachial artery, the responses to lower body negative pressure 
were preserved for all parameters, with the exception of the 
median increase in forearm norepinephrine appearance rate, 
which was reduced from 54% to 2%  (P < .05), We conclude that 
accumulation of endogenous adenosine in the synaptic cleft 
during sympathetic stimulation can inhibit norepinephrine release 
from sympathetic nerve endings. (.Hypertension. 1996;27:933-938.)
Key Words • norepinephrine •  adenosine •  receptors, 
presynaptic •  nucleosides
I n vitro observations have indicated that A TP is 
coreleased with norepinephrine from sympathetic 
nerve endings.1 Extracellular A TP is rapidly d e ­
graded by ectophosphatases to AM P, which is subse­
quently dephosphorylated by 5 '-nucleotidase to  adeno­
sine.2'4 Then endogenous adenosine is rapidly cleared 
from the interstitium, at least in part by cellular uptake 
through specific nucleoside transporters.5 In a variety of 
in vitro models, adenosine has been shown to inhibit 
norepinephrine release from sympathetic nerve en d ­
ings.6"8 Adenosine Aj receptors are thought to be in­
volved in this inhibitory effect.7 In an elegant in vivo 
study in humans, Taddei et al9 have provided indirect 
evidence for an adenosine-mediated reduction in n o r­
epinephrine release from sympathetic nerve endings in 
humans by demonstrating an augmented forearm vaso­
constrictor response to sympathetic stimulation during 
administration of the adenosine receptor antagonist 
theophylline. However, they did not measure norepi­
nephrine release in these experiments, and in theory, 
their observations could have been explained by alter­
ations or interactions at the postsynaptic level.10'11 A part 
from the putative inhibitory action of adenosine at the
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level of sympathetic nerve endings, it must be em pha­
sized that adenosine can increase sympathetic nervous 
system activity in humans by stimulating afferent nerve 
endings in the vessel wall as well as in the carotid 
body.13-14
W e perform ed this study to investigate the effect of 
endogenous adenosine on norepinephrine release from 
sympathetic nerve endings during stimulation of the 
sympathetic nervous system. To this end, a specific 
nucleoside transport inhibitor, draflazine, was used as a 
pharmacological tool to allow accumulation of endoge­
nous adenosine in the synaptic cleft during sympathetic 
stimulation.5’14 We performed appropriate pilot studies 
to determ ine the draflazine dose at which an optimal 
grade of nucleoside transport inhibition was induced. 
T he  current observations support the hypothesis that 
endogenous adenosine inhibits norepinephrine release 
at the sympathetic nerve ending.
Methods
A fter the study had been approved by the local ethics 
comm ittee, a total num ber of 35 nonnotensive, nonsmoking, 
healthy m ale volunteers signed written informed consent state­
m ents before participation in the study. Their demographic 
characteristics are summarized in Table L Ten of these subjects 
participated in the draflazine dose-finding study and 25 partic­
ipated in the main study. Subjects had no history of hyperten­
sion, diabetes mellitus, o r drug allergy and did not use concom­
itant medication. In all volunteers, a physical examination and 
1 2 -lead electrocardiography were perform ed to exclude cardio­
vascular, pulmonary, or neurological disease. The subjects were 
asked to abstain from caffeine-containing products for at least 
24 hours because low concentrations of caffeine have been 
shown to attenuate the effects of adenosine in the forearm 
vascular b e d .15 All experiments were perform ed in the morning
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Selected Abbreviations and Acronyms
Cl -  95% confidence interval 
FBF = forearm blood flow 
FVR = forearm vascular resistance 
LBNP = lower body negative pressure
after a 10-hour fasting period, in a temperature-controlled 
room (24° to 25°C), and with subjects in the supine position. 
Since all drug and volume infusion rates were calculated per 
deciliter of forearm tissue, forearm volume was measured by 
water displacement for each individual.
After local anesthesia (2% xylocaine), the left brachial artery 
was cannulated with a 20-gauge catheter (Angiocath, Deseret 
Medical, Becton Dickinson) for both intra-arterial drug infu­
sion (automatic syringe infusion pump, type STC-521, Terumo) 
and blood pressure recording (Hewlett-Packard GmbH). In the 
same arm, a deep antecubital vein was cannulated retrogradely 
for venous blood sampling. In the opposite arm, an antecubital 
vein was cannulated for blood sampling (dose-finding study) or 
infusion of tritiated norepinephrine (main study). FBF was 
recorded in both forearms by electrocardiography-triggered 
venous-occlusion plethysmography with the use of mercury- 
in-Silastic strain gauges (EC4, DE Hokanson). The upper-arm 
collecting cuffs were simultaneously inflated with a rapid cuff 
inflator (Hokanson E-20). At least 1 minute before FBF 
measurements were made, the hand circulation was occluded 
by inflation of the wrist cuffs to 200 mm Hg. FBF was recorded 
three times a minute. All experiments were started at least 30 
minutes after intra-arterial cannulation, In all experiments, the 
total intra-arterial infusion rate was kept constant at 50 /xL/100 
mL forearm per minute. Before the start of each experiment, 
venous blood was collected for measurement of plasma caffeine 
concentration.
Draflazine Dose-Finding Study
The aim of the dose-finding study was to determine the intra- 
arterial draflazine dose that resulted in a sufficient level of 
nucleoside transport inhibition in the forearm vascular bed 
without causing systemic effects and without inducing regional 
vasodilation. We reasoned that prevention of draflazine-in- 
duced vasodilation was important because baseline vascular 
tone is an important determinant of the magnitude of the 
response to vasomotor stimuli.16
In 10 subjects, the effect of five increasing doses of drafla­
zine, infused into the brachial artery, on forearm vascular tone 
and local and systemic ex vivo nucleoside transport inhibition 
was studied. The experiment started with measurement of 
baseline FBF, mean arterial pressure, and FVR during the last
4 minutes of a 5-minute saline infusion. The effect of five
T able 1. Baseline Characteristics of the Study Groups
Parameter Dose-Finding Study Main Study
n 10 25
Age, y 29.4±11.9 34.6±16.8
Weight, kg 73.3±11.5 76.0±10.4
Height, cm 180.5±9.4 181.4±6.6
Body mass index, kg/m2 22.4±2.0 23.0+2.5
Systolic BP, mm Hg 128±8.0 126±8.9
Diastolic BP, mm Hg 74.0±9.6 72.5±8.9
Heart rate, bpm 70,0±12.1 66.4±9,7
FVR, AU 55 ±11 42±15.6
Forearm volume, L 1.01 ±0.16 1.11 ±0,13
BP indicates blood pressure; AU, arbitrary units. BP was measured 
with subjects in the supine position by the Riva-Rocci technique using 
Korotkoff phases I and V for systolic and diastolic BPs, respectively. Heart 
rate was measured by pulse frequency counting (radial artery). Values are 
mean±SD.
increasing doses of draflazine (100, 250, 500, 1000, and 2000 
ng/100 mL forearm per minute) on FBF and FVR were 
compared with the effect of saline. Each draflazine dose was 
infused for 20 minutes. A t the end of saline infusion and each 
draflazine infusion, venous blood was sampled from both arms 
for ex vivo measurements of nucleoside transport inhibition 
(see “Analytic Methods”). Prolonged occlusion of the hand 
circulation can cause discomfort; therefore, wrist cuffs were 
inflated only during the last 10 minutes of draflazine infusion, 
and FBF was measured during the last 8 minutes of each 
draflazine dose.
Main Study
In 25 subjects, the lower body was sealed in an air-tight 
Plexiglas box. The applied LBNP was recorded by a manometer 
connected to the inside of the box. In each subject, a 15-minute 
LBNP at -2 5  mm Hg was applied twice. The second LBNP 
was performed 50 minutes after the first one. In a pilot study, 
we have shown that the mean hemodynamic response to LBNP 
was identical when repeated within 1 day, with a fall in FBF of 
1.3±1.0 and 1.1 ±0.8 mL/100 mL forearm per minute for the 
first and second LBNP, respectively (n=15, unpublished data, 
1995).
Intra-arterial infusion of placebo (0.9% NaCI) started 10 
minutes before each LBNP. The first LBNP was performed 
during ongoing intra-arterial placebo infusion. In contrast, 5 
minutes before the second LBNP, intra-arterial placebo was 
switched to draflazine (250 ng/100 mL forearm per minute), 
which was infused until the end of LBNP. This draflazine dose 
was based on the results of the dose-finding study. The wrist 
cuffs were inflated during the 10 minutes before each LBNP 
and during the last 10 minutes of LBNP. FBF was measured 
during the placebo infusions, during the draflazine infusion, 
and during the last 8 minutes of each LBNP. Venous and 
arterial blood samples were obtained from the infused arm 
immediately before and at the end of each LBNP for determi­
nation of norepinephrine kinetics. Additionally, arterial and 
venous blood was sampled at the end of the second placebo 
infusion for detection of a possible effect of draflazine on 
baseline norepinephrine kinetics.
Levo-[ring-2,5,6-3H]norepinephrine (specific activity, 30 to 
60 Ci/mmol) was infused intravenously for assessment of 
plasma norepinephrine kinetics. The radiotracer was adminis­
tered intravenously at a constant rate of 1.0 /xCi/min, and this 
infusion was started 20 minutes before the onset of each LBNP. 
Samples of the infúsate were taken at the end of the infusion 
for determination of the exact infusion rate and the^original 
activity of [3H]norepinephrine in a 1.0-mL plasma sample.
Analytic Methods
Samples for determination of plasma caffeine concentration 
were analyzed with a reversed-phase high-performance liquid 
chromatographic method (detection limit, 0.2 /¿g/mL), as de­
scribed previously. 17
Blood samples for determination of plasma norepinephrine 
were collected in prechilled tubes containing glutathione (0.2  
mol/L) and EGTA (0.25 mol/L). The tubes were centrifuged at 
4°C, and the plasma was separated and stored at — 20°C. 
Measurements for concentrations of norepinephrine and [3H]- 
norepinephrine of all plasma samples and infusates occurred 
within 2  months after sampling, using high-performance liquid 
chromatography with fluorimetric detection after precolumn 
derivatization with the fluorescent agent 1,2 -diphenylethyl- 
enediamine. A fraction collector (model 201-202, Gilson Med­
ical Electronics), that was connected to an automatic sample 
injector (Wisp 710B), was used for collection of [3H]norepi- 
nephrine into scintillation vials according to the retention time 
of the norepinephrine standard solution.
Ex vivo nucleoside transport inhibition was measured by 
standardized incubation of erythrocytes with adenosine. Blood 
(4 mL) was drawn into a vial containing 1.0 mL acid/citrate/
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dextrose (65 mmol/L citric acid, 85 mmol/L trisodium citrate, 
and 20 g/L glucose) and further handled as described previous­
ly. 14 After incubation, the concentrations of adenosine, inosine, 
and hypoxanthine were determined in the supernatant by a 
chemiluminescence technique. The percent inhibition of nucle­
oside transport was calculated as (Ax- A ())x  100/(1-A„), where 
A0 represents the adenosine concentration as a proportion of 
the sum of the concentration of adenosine, inosine, and 
hypoxanthine as determined in the sample collected just before 
the drug infusion; and Ax represents this proportion as deter­
mined in the sample collected after the start of the drug 
infusion.
Drugs and Solutions
Tritiated norepinephrine was obtained from DuPont-New 
England Nuclear. The radionuclide was sterilized with a
0.22-jum filter and diluted in 0.9% NaCl containing acetic (0.2 
mol/L) and ascorbic (1 mg/mL) acids. Aliquots of approxi­
mately 70 jiiCi/mL of [:,H]norepinephrine were stored at -80°C  
until use. Sterilization, dilution, and aliquotingwere carried out 
under nitrogen. Just before use, an aliquot was diluted in 0.9% 
NaCl.
Sterile draflazine solutions were freshly prepared from 
10-mL vials containing 5 mg draflazine diluted in 0.9% NaCl 
(Janssen Pharmaceutica Inc). The specificity of this drug as a 
nucleoside transport inhibitor and its ability to increase endog­
enous adenosine levels in humans have been extensively de­
scribed before .5*14
Data Analysis
Mean arterial blood pressure was measured continuously 
during each recording of FBF and averaged per FBF measure­
ment. FVR was calculated as the quotient of the simulta­
neously registered mean arterial blood pressure and FBF and is 
expressed as arbitrary units (AU). For the draflazine dose- 
finding study, the hemodynamic registrations obtained during 
placebo infusion and the last 6 minutes of each draflazine 
infusion were each averaged to one value. Drafiazine-induced 
eifects were expressed as both absolute and percent changes 
from the preceding placebo infusion. For the main study, the 
hemodynamic parameters were averaged to one value for the 
following consecutive periods: placebo-1, placebo plus LBNP, 
placebo-2, draflazine, and draflazine plus LBNP. The data 
obtained during the last 6 minutes of each LBNP were used.
Arterial and venous concentrations of pH]norepinephrine 
and norepinephrine were used for calculations of the various 
parameters of norepinephrine kinetics, as previously de­
scribed. 1^ 20 Total body norepinephrine spillover, the estimated 
rate of appearance of endogenous norepinephrine in arterial 
plasma, was calculated from arterial plasma norepinephrine 
concentration (NEa), the arterial steady-state plasma concen­
tration of [3H]norepinephrine ([3H]NEa), and the infusion rate 
of [3H]norepinephrine according to the equation
Total Body Norepinephrine Spillover (ng/min)
= N Ea(ng/L)
X{Infusion Rate (dpm/min)}/[3H]NEa(dpm/L)
where dpm is disintegrations per minute. The local forearm 
norepinephrine appearance rate was estimated from
Forearm Norepinephrine Appearance Rate 
(pg/100 mL forearm per minute)
= {(FPFx NEa X fNE)+ [FPF x (NEv-N E a)] }/(l -  fNE)
where fNF is the fractional extraction of the tracer across the 
forearm, calculated as ([3H]NEa- [ 3H]NEv)/[3H]NEa; [3H]NEV 
and [3H]NEa are the venous and arterial plasma concentrations
of [3H]norepinephrine, respectively; and FPF is the forearm 
plasma flow (milliliters per 100 mL forearm per minute), 
calculated from FBF and hematocrit as F B F X (l-H t) .
Changes in the hemodynamic and kinetic parameters in­
duced by LBNP during placebo were compared with those 
induced by LBNP during draflazine.
All hemodynamic results are presented as m ean± S E  unless 
indicated otherwise. The data on forearm norepinephrine 
appearance rate and norepinephrine total body spillover are 
presented as median with CI. To avoid multiple comparison, 
within-subject effects were first assessed by ANOVA for re­
peated measurements and further analyzed with paired Stu­
dent’s t test if appropriate (dose-finding study). The results of 
the main study were analyzed by paired Student’s t tests 
because these data sets showed gaussian distributions accord­
ing to the Shapiro-Wilks test. To minimize multiple compari­
sons, LBNP-induced changes from baseline were not tested 
statistically. For the same reason, only the key parameters were 
included in the statistical analysis (FVR, forearm norepineph­
rine appearance rate, and total body spillover). Differences 
were considered to be statistically significant at a value of 
ƒ*<.05 (two-sided).
Results
We determined plasma caffeine levels to check com­
pliance with respect to caffeine abstinence. In all volun­
teers, plasma caffeine concentrations were below the 
limit of detection, indicating excellent compliance to the 
caffeine-free diet. No subjective side effects occurred 
during the intra-arterial infusion of draflazine.
Dose-Finding Study
Baseline FBF was 2.1 ±0.3 mL/100 mL forearm per 
minute in the cannulated arm and increased to 2.2 ±0.4, 
2.4±0.3, 3.0±0.4, 3.7±0.5, and 4,2±0.5 mL/100 mL fore­
arm per minute at the end of the five increasing draflazine 
doses, respectively. Expressed as percent change from 
baseline, FBF was increased by 4.9±7.4%, 18.0±6.1%, 
51.1 ±13.6%, 94.1 ±20.8%, and 123.2±24.5% at the end of 
the five increasing draflazine doses, respectively (n=10, 
P<.05 for the four highest doses). FBF in the contralat­
eral arm was not significantly affected during any of the 
infusions. Baseline FVR was 54.6±10.7 AU in the 
cannu la ted  arm. Draflazine decreased  F V R  by
5.3± 10.1%, 5.7±5.7%, 20.4±6.7%, 34.8±7.1%, and 
41.7±6.7% for 100, 250, 500, 1000, and 2000 ng drafia- 
zine/100 mL forearm per minute, respectively (n=10, 
P C .05 for the three highest doses). FV R in the con­
tralateral arm was not significantly affected (Fig 1).
In the infused arm, ex vivo nucleoside transport 
inhibition was 7.0±2.4%, 42.4±8.8%, 69.7±7.7%, 
80.8±4.8%, and 87.1 ±2.5% during the five increasing 
doses, respectively (n=10, P<.05 for each dose versus 
baseline; see Fig 1), Likewise, in the nonexperimental 
arm, ex vivo nucleoside transport inhibition increased 
dose dependency by 3.9±1.6%, 6.8±3.4%, 11.9±3.7%, 
17.8±3.5%, and 51.2±3.0%, respectively (n=10, P< .05 
for each dose versus baseline; see Fig 1).
On the basis of these results, the draflazine dose of 
250 ng/100 mL forearm per minute was chosen for the 
main study because this dose induced a sufficient nucle­
oside transport inhibition in the forearm vascular bed 
(approximately 40%), without a relevant increase in this 
parameter at the contralateral site (approximately 7%) 
and without causing a significant vasodilator response at 
the site of infusion.
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Fig 1. Percent changes (mean±SE) in nucleoside transport 
inhibition (left) and FVR (right) induced by incremental doses of 
draflazine infused into the brachial artery. The solid line repre­
sents data at the side of draflazine infusion; the dashed line, data 
from the contralateral side. *P<.05 vs baseline.
Main Study
Effect of Sympathetic Stimulation by LBNP
Table 2 shows the hemodynamic and neurohumoral 
effects of LBNP with and without concomitant intra- 
arterial draflazine infusion. During placebo, LBNP in­
duced a fall in FBF from 2.6±0.3 to 1.5±0.2 mL/100 mL 
forearm per minute at the experimental side and from 
2.5 ±0,3 to 1.5 ±0.2 mL/100 mL forearm per minute at 
the contralateral side. Mean arterial blood pressure did 
not change, but heart rate increased by 5.2±1.6% as a 
result of the first LBNP. Total body norepinephrine 
spillover increased by 26.2% (Cl, 11.3% to 41.5%), 
whereas the forearm norepinephrine appearance rate 
increased by 53.5% (CI, -0.6%  to 97.9%). Fifty minutes 
after the first LBNP was stopped, all parameters had 
returned toward baseline level (placebo-1).
Effects of Draflazine Infusion
In accordance with the results of the dose-finding 
study, intra-arterial infusion of draflazine at a rate of 250 
ng/100 mL forearm per minute hardly affected vascular 
tone (Table 2). Although total body norepinephrine 
spillover was not altered, draflazine caused an increase 
in forearm norepinephrine appearance rate of 19.4% 
(CI, 6.3% to 47.0%) (ƒ*<.01 versus baseline).
Effects of Draflazine on the Response to Sympathetic 
Stimulation by LBNP
Application of LBNP during draflazine exerted a 








Fig 2. LBNP-induced percent changes in forearm norepineph­
rine appearance rate (open boxes) and total body norepineph­
rine spillover (shaded boxes). Boxes represent the interquartile 
range; capped bars, 10th and 90th percentiles of individual data. 
Dots mark all data outside the 5th and 95th percentiles. *Statis- 
tically significant difference between saline and draflazine 
(P<.05, two-tailed paired Student’s ttest).
response to the first LBNP, with no change in mean 
arterial blood pressure and a significant increase in heart 
rate of 7.3 ±2.0%. During draflazine infusion, LBNP 
induced a fall in FBF from 3.2±0.4 to 2.1 ±0.3 mL/100 
mL forearm per minute at the experimental side and 
from 2.8±0.3 to 1.9±0.2 mL/100 mL forearm per minute 
at the contralateral side. FVR showed a bilateral fall 
without a difference between the experimental and 
contralateral sides, although the response was lower on 
both sides compared with the first LBNP.
Fig 2 shows the LBNP-induced percent changes from 
baseline for the data on norepinephrine. Again, total 
body norepinephrine spillover increased by a median
percent change of 32.7% (CI, 19.8% to 62.8%) as 
opposed to 26.2% (CI, 11.3% to 41.5%) during the first 
LBNP (first versus second LBNP, P ~ .2). In contrast, the 
response of forearm norepinephrine appearance rate to 
LBNP was almost abolished during draflazine, this re­
sponse being significantly lower compared with that to 
the first LBNP (2.2% [CI, —11.4% to 40.4%] versus 
53.5% [CI, -0 .6%  to 97.9%]; Pc.05).
Discussion
The main observation of this study is that infusic/n of 
the specific nucleoside transport inhibitor draflazinp into 
the forearm skeletal muscle vascular bed resulted in a




FVR infused arm, AU
FVR control arm, AU
Total body norepinephrine spillover, 
ng/min
Forearm norepinephrine appearance rate, 
(pg/100 mL)/mln
First Placebo First LBNP Placebo Draflazine Second LBNP
41.5±3.1 86.7±12.6 39.7±3.2 38.1 ±3 .0 64.5 ± 7.5
(100.7+16.4%) (-3 .4±1.9% ) (65.9± 10.5%)t
44.0±3.8 92.3±14.5 49.2±6.5 45.9±5.2 78.3 ± 11.4
(102,6±19.4%) (-3 .6±2,8% ) (68.5 ± 12.2%)t
344.5 439.1 352.2 356.5 507.1
(26.2%; Cl, 11.3-41.5%) (-0.6%; Cl, -8-3.2% ) (32.7%; Cl, 19.8-62.8%)
549.0 732.1 692.0 766.5 922.3
(53.5%; Cl, -0.6-97.9%) (19.4%; Cl, 6.3-47%)* (2.2%; Ci, - -11.4-40.4%)t
AU indicates arbitrary units. Values are meaniSE for FVR data and median for norepinephrine data. Percent changes from baseline are shown in 
parentheses (mean±SE for FVR data and median plus Cl for norepinephrine data).
Statistically significant changes from baseline (tested only tor draflazine); tstatlsticaily significant differences in percent response between first and 
second LBNP.
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blunted response of the local norepinephrine appear­
ance rate during sympathetic stimulation. This attenua­
tion occurred only at the side of draflazine infusion, as 
simultaneous measurements of total body norepineph­
rine spillover convincingly showed that the overall re­
sponse of the sympathetic nervous system to LBNP 
during draflazine (median, 32.7%) was certainly not 
lower than that to LBNP during placebo (median, 
26.2%). The absence of an effect on total body norepi­
nephrine spillover agrees with the almost negligible level 
of systemic nucleoside transport inhibition, which was 
far below the threshold for interference with the sympa­
thetic nervous system.14 The specificity of draflazine has 
been tested in various in vitro systems.21 Intravenous 
infusion of draflazine in conscious humans elicits hemo­
dynamic, neurohumoral, and ventilatory responses that 
closely resemble the effects of intravenous infusion of 
adenosine.12’14’22'25 This occurred at higher systemic 
draflazine blood concentrations than currently used lo­
cally, as assessed by ex vivo nucleoside transport inhibi­
tion. By use of caffeine as an adenosine receptor antag­
onist, we were able to show in a previous study that the 
circulatory effects of nucleoside transport inhibition by 
draflazine resulted entirely from adenosine receptor 
stimulation.14 Consequently, our current data provide 
evidence for an adenosine receptor-mediated reduction 
in norepinephrine release from efferent nerve endings 
during sympathetic stimulation. This reduction in the 
observed LBNP-induced norepinephrine release from 
the forearm vascular bed was expected to be accompa­
nied by a parallel reduction in the local vasoconstrictor 
response to sympathetic stimulation. However, we did 
not find any evidence for an impaired forearm vasocon­
strictor response at the side of draflazine infusion (Table 
2). This does not necessarily argue against our interpre­
tation of the results, because the forearm vasoconstrictor 
response also depends on a variety of other factors, 
including the postsynaptic interaction between adeno­
sine and norepinephrine,10’11 eventual alterations in re­
ceptor populations, and changes in the release of co- 
transmitters such as ATP and neuropeptide Y.1-26*27 Of 
course, possible actions of draflazine unrelated to nucle­
oside transport inhibition may contribute to the effects 
seen in this study.
Our interpretations are mainly based on assessment of 
the spillover of norepinephrine according to the isotope 
dilution technique as described by Esler et al.19 The 
tracer [3H]norepinephrine is used for determination of 
the amount of norepinephrine extracted during passage 
across a vascular bed, in this case, that of the forearm 
skeletal muscles. However, forearm norepinephrine spill­
over as calculated from these parameters strongly de­
pends on FBF.18 Recently, Chang et al20 proposed a 
correction for this calculated forearm norepinephrine 
spillover by taking into account the amount of released 
norepinephrine that is also extracted from the forearm 
vascular bed. This so-called forearm norepinephrine 
appearance rate should be a more accurate measure­
ment of the regional release of norepinephrine, espe­
cially for our study because of the induced changes in 
FBF as a result of sympathetic stimulation.
In our dose-finding study, intra-arterial infusion of 
draflazine resulted in a significant dose-dependent inhi­
bition of ex vivo nucleoside transport that was consider­




Fig 3. Outline of the potential interactions between endoge­
nous adenosine and the sympathetic nervous system. NE indi­
cates norepinephrine.
noninfused contralateral arm. Draflazine doses of 500 
ng/100 mL forearm per minute or more elicited vasodi­
lation in the infused arm that was not observed in the 
control arm, indicating a local vasodilator action of 
draflazine in humans. As demonstrated previously, the 
effects of draflazine are mediated by adenosine accumu­
lation in the extracellular space and subsequent adeno­
sine receptor stimulation.14 Therefore, the vasodilator 
action of draflazine indicates extracellular adenosine 
accumulation in the nonischemic human forearm vascu­
lar bed. Possible sources of this endogenous adenosine 
include endothelium, vascular smooth muscle cells, and 
sympathetic nerve endings where adenosine is formed 
extracellularly by enzymatic degradation of the neuro­
transmitter ATP.28-31 
Unexpectedly, the main study showed that baseline 
forearm norepinephrine appearance rate increased sig­
nificantly during draflazine infusion without changes in 
total body norepinephrine spillover. Actually, the dose 
of 250 ng/100 mL forearm per minute was chosen 
because it was expected to inhibit nucleoside transport 
inhibition to a sufficient extent without affecting baseline 
hemodynamic or humoral parameters. Of course, we 
realized that increasing endogenous adenosine levels 
may stimulate sympathetic nervous system activity by 
stimulation of afferent nerves.12-14 Recently, this has 
been shown in particular for the forearm skeletal muscle 
vascular bed.32 However, dose-response data on drafla­
zine have suggested that this afferent stimulation should 
not occur at the level of nucleoside transport inhibition 
reached in our main study.14 Nonetheless, the present 
finding indicates that the baseline norepinephrine re­
lease from sympathetic nerve endings in the forearm can 
be slightly stimulated by low doses of intra-arterially 
infused draflazine. We have no clear explanation for this 
observation. If stimulation of adenosine-sensitive affer­
ent nerve endings in the forearm vascular bed plays a
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role in this observation, we must assume that the re­
sponse of the efferent sympathetic nervous system was a 
differential side-selective response because total body 
norepinephrine spillover and systemic hemodynamics 
were unaffected. Along these lines, the contrasting ef­
fects of draflazine on baseline versus stimulated forearm 
norepinephrine appearance rate may be mediated by 
interaction of endogenous adenosine with the sympa­
thetic nervous system at two distinct levels. Fig 3 sum-
marizes this hypothesis.
First, accumulation of continuously formed interstitial 
adenosine may increase sympathetic nervous system 
activity as a result of stimulation of afferent nerve 
endings in the forearm vascular bed. Second, during 
sympathetic stimulation, draflazine allows accumulation 
of endogenous adenosine, as a breakdown product of 
ATP coreleased in the synaptic cleft that is able to 
reduce norepinephrine release from sympathetic nerve 
endings locally by presynaptic inhibition of neurotrans­
mitter release. Apparently, the first effect of adenosine 
dominates during baseline conditions, when baseline 
sympathetic nervous system activity is low. However, the 
importance of the second interaction increases during 
sympathetic stimulation by LBNP as adenosine builds up 
in the synaptic cleft. It has to be emphasized that this 
dual action of adenosine has already been extensively 
described for exogenous adenosine.33 The current re­
sults extrapolate this concept to the effects of endoge­
nous adenosine.
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